Sales grew 16% at constant exchange rates to CHF 3.4 billion, with CORE EBITDA margin up 4.4 points to 34.8%. All segments delivered strong growth, and the 2026 outlook was upgraded. The Capsules & Health Ingredients business was divested for CHF 2.3 billion.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.